Rabeprazole + clopidogrel vs omeprazole + clopidogrel vs clopidogrel alone in volunteers with different CYP2C19 genotypes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2011

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Clopidogrel (Primary) ; Omeprazole (Primary) ; Rabeprazole (Primary)
Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Duodenal ulcer; Dyspepsia; Embolism and thrombosis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Reflux oesophagitis; Stroke; Unstable angina pectoris; Zollinger-Ellison syndrome
Focus Pharmacodynamics; Pharmacogenomic

17 Nov 2011 New trial record
02 Nov 2011 Results presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com